- Conditions
- Dementia
- Interventions
- meals, AES 8 basic usage, AES 8 advanced usage
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 233
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nicotine Dependence
- Interventions
- Placebo, Varenicline
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- INT-747, Ursodeoxycholic Acid (URSO), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more
- Conditions
- Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
- Interventions
- Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
- Interventions
- M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
- Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed Adult Acute Myeloid Leukemia, Refractory Adult Acute Myeloid Leukemia
- Interventions
- Merestinib, LY2874455
- Drug
- Lead sponsor
- Jacqueline Garcia, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia
- Interventions
- MK-8189, Placebo, Background AAP Therapy
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
- Interventions
- Photobiomodulation, Routine Oral Care and Analgesia
- Device · Other
- Lead sponsor
- MuReva Phototherapy Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Long Beach, California • Miami, Florida + 9 more
- Conditions
- Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement, Relapsed Cancer, MET Amplification, Resistant Cancer, NSCLC
- Interventions
- Lorlatinib, Crizotinib, Binimetinib, TNO155
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Postural Tachycardia Syndrome
- Interventions
- Placebo oral tablet, Moxonidine Pill
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Critically Ill
- Interventions
- Once daily screening, Twice daily screening, PS SBTs, T-piece SBTs
- Procedure
- Lead sponsor
- Unity Health Toronto
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Long Beach, California • Los Angeles, California • Boston, Massachusetts + 2 more
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Symptoms and Signs, Physical Inactivity, Muscle Loss
- Interventions
- LiverWatch Intervention
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Philadelphia, Pennsylvania
- Conditions
- Concussion, mTBI, Post-Concussive Symptoms, Chronic Headache, Chronic Insomnia, Chronic Attention Disorder
- Interventions
- Neurofeedback (NFB)
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
- Interventions
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Drug
- Lead sponsor
- Patrick C. Johnson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 64 more
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®
- Drug
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • New York, New York
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Rivaroxaban
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 5
- States / cities
- Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae
- Interventions
- GSK1349572, Efavirenz
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
- Interventions
- e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning, GVHD Prophylaxis, Allogeneic HSC, Bisulfan, Prednisone, Cyclophosphamide, MMF, Mesna, Tacrolimus, Pentostatin, PFTs, DEXA, Bone Marrow Aspirate & Biopsy, EKG, 2D ECHO
- Drug · Procedure · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2030
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Adenoid Cystic Carcinoma, Salivary Gland Cancer
- Interventions
- Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 8
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- HIV-1
- Interventions
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more
- Conditions
- Peripheral Artery Disease, Intermittent Claudication, Peripheral Vascular Disease, Mobility Limitation, Revascularization
- Interventions
- Home Based Exercise, Nitrate Rich Beetroot Juice, Attention Control, Placebo Beetroot Juice Without Nitrate
- Behavioral · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Downey, California • Atlanta, Georgia + 3 more
- Conditions
- Depressive Symptoms
- Interventions
- Resiliency Class, Resource for Services (RS)
- Behavioral · Other
- Lead sponsor
- Bowen Chung, MD, MSHS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 22
- States / cities
- Compton, California • Long Beach, California • Los Angeles, California + 1 more
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
- Procedure · Behavioral · Drug + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Decatur, Georgia